2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
2
Myocardial Reperfusion Injury
2
Cardiotoxicity
2
Vomiting
1
Uveal Melanoma
1
Thrombosis
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Reperfusion Injury
1
Pain, Postoperative
1
Opioid-Related Disorders
1
Nausea
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Choroid Diseases
1
Breast Neoplasms
1
Interventions
Ipilimumab
29
Nivolumab
23
pembrolizumab
14
incomplete Freund's adjuvant
10
Cyclophosphamide
10
Melphalan
9
Interleukin-2
9
CTLA-4 Antigen
8
tebentafusp
7
sargramostim
7
Temozolomide
7
MART-1 Antigen
7
Dacarbazine
7
Ranibizumab
6
montanide ISA 51
5
fludarabine phosphate
5
fludarabine
5
Sunitinib
5
Radiosurgery
5
Carboplatin
5
Blood Specimen Collection
5
Bevacizumab
5
aldesleukin
4
aflibercept
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
trametinib
3
sotrastaurin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
salicylhydroxamic acid
×
Clear all
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled